^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Oncotarget
    Title:

    Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

    Excerpt:
    The level of HER2 protein expression was significantly associated with resistance to panitumumab (Fisher's exact test, P = 0.035).
    DOI:
    10.18632/oncotarget.8006
    Trial ID:
    NCT00853931